KULA, MAUI, Hawaii, April 22 /PRNewswire-FirstCall/ -- Bioponic Phytoceuticals, Inc. (OTC Bulletin Board: BPYT) ("Bioponic" or "the Company") today announced that Dr. Barbara Anne Nabrit-Stephens, MD, MBA, FAAP has joined the Company's Scientific Advisory Board. Dr. Nabrit-Stephens is a board-certified pediatrician with over 30 years of health care experience. As a scientific advisor, Dr. Nabrit-Stephens will help validate and formulate Bioponic's strategies to market its all-natural therapeutic products, including Curecumin(TM) and Curmisinin(TM).
"We are honored to welcome Dr. Nabrit-Stephens to our Scientific Advisory Board. Dr. Nabrit-Stephens' in-depth experience as both a clinician and health care administrator is a true asset to our organization," said Steven M. Schorr, Chairman and CEO of Bioponic. "Testing and research programs for Alzheimer's applications for Curecumin(TM) and distribution of Curmisinin(TM) to treat the deadly cerebra malaria, which kills over 2 million children in Sub-Saharan Africa, are the first projects Dr. Nabrit-Stephens will be involved in. She is also ideally suited to advise us on our newest product line, Gentle Mother, specifically for the needs of newborns and infants."
Dr. Nabrit-Stephens said, "I've always been attracted to those companies who focus on providing pro-active healthcare solutions, especially to those populations at-risk. Bioponic's work in bringing all-natural treatments to control devastating malaria in Africa is very impressive. I believe Bioponic's Bioresonant formulations could potentially represent a breakthrough in the treatment of epidemic disease. I am intrigued to discover more about the Company and their product lines, and look forward to our ongoing collaboration."
Dr. Nabrit-Stephens earned her medical degree from Tufts University in 1976, her BA from Harvard University in 1972, and her MBA from the University of Tennessee in 1998. She served as a private pediatrician for years in Nashville, Tennessee, before she joined the health-care administration industry in the late 1990s. Dr. Nabrit Stephens is currently Medical Director of Care Management at Blue Cross Blue Shield of Florida in Tampa. Prior to joining BC/BS in 2006, Dr. Nabrit-Stephens was Vice President, Medical Affairs at Keystone Mercy Health, Southeastern Pennsylvania's largest medical assistance managed health care plan organization from 2003 to 2005. Her previous administrative professional positions include Medical Director at OmniCare Health Plan and Plan Medical Director at Tennessee Managed Care Network.
Dr. Nabrit-Stephens also has a wealth of experience in academia. She has served as an assistant professor, director of education for the Department of Pediatrics, Meharry Medical College, and an assistant clinical professor at the Vanderbilt University School of Medicine. In addition, she has done varied research, particularly in the area of HIV/AIDS, where she worked with pregnant women who were HIV-positive and transmitting the virus from mother to baby.
About Bioponic Phytoceuticals
Bioponic Phytoceuticals is engaged in the development, production and distribution of Bioresonant Phytotherapeutic(TM) products. The Company has developed several branded product lines (including the nasal spray: Flight Spray(R) (http://www.flightspray.com) and the skincare product Hawaiian Healing Mist(TM)). Bioponic is focused on the production of natural products that are used to promote health and well-being. Visit http://www.bioponic.com.
All statements other than statements of historical fact included in this press release are "forward-looking statements" within the meaning of federal securities laws. Such forward-looking statements are subject to a number of risks and uncertainties, some of which are beyond the Company's control.
CONTACT: Steven M. Schorr, CEO, Bioponic Phytoceuticals, +1-808-876-1711, email@example.com or Rick McCaffrey, Investor Relations, OTC Financial Network, 781-444-6100x625, firstname.lastname@example.org, http://www.otcfn.com/bpyt.
|SOURCE Bioponic Phytoceuticals|
Copyright©2008 PR Newswire.
All rights reserved